Latest & greatest articles for geriatrics

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on geriatrics or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on geriatrics and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for geriatrics

81. Respiratory rehabilitation in elderly patients with COVID-19: A randomized controlled study Full Text available with Trip Pro

Actions Cite Share Permalink Copy Page navigation Randomized Controlled Trial Complement Ther Clin Pract Actions . 2020 May;39:101166. doi: 10.1016/j.ctcp.2020.101166. Epub 2020 Apr 1. Respiratory Rehabilitation in Elderly Patients With COVID-19: A Randomized Controlled Study , , , , , Affiliations Expand Affiliations 1 Department of Geriatric Center, Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), Haikou, 570311, PR China. 2 Department of General Surgery, Hainan (...) Rehabilitation in Elderly Patients With COVID-19: A Randomized Controlled Study Kai Liu et al. Complement Ther Clin Pract . 2020 May . Free PMC article Show details Complement Ther Clin Pract Actions . 2020 May;39:101166. doi: 10.1016/j.ctcp.2020.101166. Epub 2020 Apr 1. Authors , , , , , Affiliations 1 Department of Geriatric Center, Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), Haikou, 570311, PR China. 2 Department of General Surgery, Hainan General Hospital (Hainan

2020 EvidenceUpdates

82. Strategies For Risk Reduction and Management of Older Adults With Cardiovascular Disease During the COVID-19 Pandemic

Strategies For Risk Reduction and Management of Older Adults With Cardiovascular Disease During the COVID-19 Pandemic Strategies For Risk Reduction and Management of Older Adults With Cardiovascular Disease During the COVID-19 Pandemic - American College of Cardiology ') Search All Types Search or Menu . This article was authored by Nicole M. Orr, MD, FACC , and the Geriatric Cardiology Council. Share via: Clinical Topics: Keywords: Aged, SARS Virus, Angiotensin Receptor Antagonists (...) , Hydroxychloroquine, Mineralocorticoid Receptor Antagonists, Caregivers, Angiotensin-Converting Enzyme Inhibitors, COVID-19, Coronavirus, Coronavirus Infections, Neprilysin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Neprilysin, Chloroquine, Subacute Care, Social Isolation, Skilled Nursing Facilities, Cardiovascular Diseases > > Strategies For Risk Reduction and Management of Older Adults With Cardiovascular Disease During the COVID-19 Pandemic Heart House 2400 N Street NW Washington, DC 20037 Phone: , ext

2020 American College of Cardiology

83. Community-based health promotion for older adults

and outcomes for people aged over 60 years? 13 Grey Literature 24 Gaps in the evidence 25 Discussion 26 Applicability 28 References 31 Appendix A 35 Appendix B 36 Appendix C 45 Appendix D 46 COMMUNITY-BASED HEALTH PROMOTION FOR OLDER ADULTS APRIL 2019 | SAX INSTITUTE 5 Executive summary Background Older adults who are physically active maintain better health and cognitive function than adults who are not. Evidence-based strategies to increase health and wellbeing among older people are needed (...) Question 1: What community-based programs, that combine physical activity, with other activities addressing key health risk factors, have shown to be effective in improving the health behaviours and outcomes for people aged over 60 years? The evidence check identified 26 papers reporting on 23 different community-based programs for older adults (60+ years) that met the criteria for inclusion in this rapid review. Programs were developed in the United States, Canada, Brazil, several European countries

2020 Sax Institute Evidence Check

84. How might the wellbeing of older people living in the community be supported when shielding and social distancing has been recommended for an extended period of time?

from a bank or post office. Consider action to ensure that older people are not concerned about being able to pay their telephone/broadband bills. Telephone communication providers should consider whether they are able to cap call and internet charges and provide unlimited use for elderly people during this period. What the evidence says We based these suggestions on the following research findings On quality of life older people report value in: ? Being able to manage on their own retaining (...) to meet basic needs o Having material resources to feel comfortable and independent 2 This review looked at qualitative research, in people aged 65 or over who were still living independently, that investigated their views about occupations that enhanced their wellbeing. Authors found that: Solitary occupations are described as positive and highly important to older people’s wellbeing. ? Older people described the need for autonomy in deciding what to do and when to do it; occupations needed

2020 Public Health Wales Observatory Evidence Service

85. Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups Full Text available with Trip Pro

Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National (...) : Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Stroke Actions . 2020 Jun;51(6):1758-1765. doi: 10.1161/STROKEAHA.119.028643. Epub 2020 May 14. Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 From the Faculty of Medicine, Institute for Medical Informatics, Biometry and Epidemiology

2020 EvidenceUpdates

86. Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study. Full Text available with Trip Pro

Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study. The medical, societal, and economic impact of the coronavirus disease 2019 (COVID-19) pandemic has unknown effects on overall population mortality. Previous models of population mortality are based on death over days among infected people, nearly all of whom thus far have underlying conditions. Models have not incorporated information on high-risk (...) by Public Health England guidelines (from March 16, 2020) in individuals aged 30 years or older registered with a practice between 1997 and 2017, using validated, openly available phenotypes for each condition. We estimated 1-year mortality in each condition, developing simple models (and a tool for calculation) of excess COVID-19-related deaths, assuming relative impact (as relative risks [RRs]) of the COVID-19 pandemic (compared with background mortality) of 1·5, 2·0, and 3·0 at differing infection

2020 Lancet

87. Effect of Antihypertensive Medication Reduction vs Usual Care on Short-term Blood Pressure Control in Patients With Hypertension Aged 80 Years and Older: The OPTIMISE Randomized Clinical Trial. (Abstract)

in systolic blood pressure control or adverse events during 12-week follow-up.The Optimising Treatment for Mild Systolic Hypertension in the Elderly (OPTIMISE) study was a randomized, unblinded, noninferiority trial conducted in 69 primary care sites in England. Participants, whose primary care physician considered them appropriate for medication reduction, were aged 80 years and older, had systolic blood pressure lower than 150 mm Hg, and were receiving at least 2 antihypertensive medications were (...) Effect of Antihypertensive Medication Reduction vs Usual Care on Short-term Blood Pressure Control in Patients With Hypertension Aged 80 Years and Older: The OPTIMISE Randomized Clinical Trial. Deprescribing of antihypertensive medications is recommended for some older patients with polypharmacy and multimorbidity when the benefits of continued treatment may not outweigh the harms.This study aimed to establish whether antihypertensive medication reduction is possible without significant changes

2020 JAMA

88. Interventions for increasing fruit and vegetable consumption in children aged five years and under. (Abstract)

Interventions for increasing fruit and vegetable consumption in children aged five years and under. Insufficient consumption of fruits and vegetables in childhood increases the risk of future non-communicable diseases, including cardiovascular disease. Testing the effects of interventions to increase consumption of fruit and vegetables, including those focused on specific child-feeding strategies or broader multicomponent interventions targeting the home or childcare environment is required (...) to assess the potential to reduce this disease burden.To assess the effectiveness, cost effectiveness and associated adverse events of interventions designed to increase the consumption of fruit, vegetables or both amongst children aged five years and under.We searched CENTRAL, MEDLINE, Embase and two clinical trials registries to identify eligible trials on 25 January 2020. We searched Proquest Dissertations and Theses in November 2019. We reviewed reference lists of included trials and handsearched

2020 Cochrane

89. In older adults with acute ischemic stroke, the Clinical Frailty Scale predicted mortality at 28 days. (Abstract)

In older adults with acute ischemic stroke, the Clinical Frailty Scale predicted mortality at 28 days. Evans NR, Wall J, To B, et al. Clinical frailty independently predicts early mortality after ischaemic stroke. Age Ageing. 2020. [Epub ahead of print]. 31951248.

2020 Annals of Internal Medicine

90. In older patients in the ED, higher ERA scores were associated with increased risk for mortality and return visits. (Abstract)

In older patients in the ED, higher ERA scores were associated with increased risk for mortality and return visits. Espinoza Suarez NR, Walker LE, Jeffery MM, et al. Validation of the Elderly Risk Assessment index in the emergency department. Am J Emerg Med. 2019. [Epub ahead of print]. 31839521.

2020 Annals of Internal Medicine

91. Web Exclusive. Annals Consult Guys - Hydroxychloroquine: Update on an Old Drug. (Abstract)

Web Exclusive. Annals Consult Guys - Hydroxychloroquine: Update on an Old Drug. [Figure: see text].

2020 Annals of Internal Medicine

92. Interventions for improving medication-taking ability and adherence in older adults prescribed multiple medications. (Abstract)

studies.We included randomised controlled trials (RCTs), quasi-RCTs, and cluster-RCTs. Eligible studies tested interventions aimed at improving medication-taking ability and/or medication adherence among people aged ≥ 65 years (or of mean/median age > 65 years), living in the community or being discharged from hospital back into the community, and taking four or more regular prescription medications (or with group mean/median of more than four medications). Interventions targeting carers of older people (...) Interventions for improving medication-taking ability and adherence in older adults prescribed multiple medications. Older people taking multiple medications represent a large and growing proportion of the population. Managing multiple medications can be challenging, and this is especially the case for older people, who have higher rates of comorbidity and physical and cognitive impairment than younger adults. Good medication-taking ability and medication adherence are necessary to ensure safe

2020 Cochrane

93. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. (Abstract)

Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Age-related macular degeneration (AMD) is one of the leading causes of permanent blindness worldwide. The current mainstay of treatment for neovascular AMD (nAMD) is intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents: aflibercept, ranibizumab, and off-label bevacizumab. Injections can be given monthly, every two or three (...) months ('extended-fixed'), or as needed (pro re nata (PRN)). A variant of PRN is 'treat-and-extend' whereby injections are resumed if recurrence is detected and then delivered with increasing intervals. Currently, injection frequency varies among practitioners, which underscores the need to characterize an optimized approach to nAMD management.To investigate the effects of monthly versus non-monthly intravitreous injection of an anti-VEGF agent in people with newly diagnosed nAMD.We searched CENTRAL

2020 Cochrane

94. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial. (Abstract)

Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial. A substantial unmet need remains for safe and effective vaccines against dengue virus disease, particularly for individuals who are dengue-naive and those younger than 9 years. We aimed to assess the efficacy, safety, and immunogenicity of a live attenuated tetravalent dengue vaccine (TAK-003) in healthy children aged 4-16 years.We present data up to 18 months post (...) -vaccination from an ongoing phase 3, randomised, double-blind trial of TAK-003 in endemic regions of Asia and Latin America (26 medical and research centres across Brazil, Colombia, Dominican Republic, Nicaragua, Panama, Philippines, Sri Lanka, and Thailand). Healthy children aged 4-16 years were randomly assigned 2:1 (stratified by age and region) to receive two doses of TAK-003 or two doses of placebo, 3 months apart. Investigators, participants and their parents or guardians, and sponsor

2020 Lancet

95. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial. (Abstract)

Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial. An unmet clinical need remains for an effective tetravalent dengue vaccine suitable for all age groups, regardless of serostatus. We assessed the immunogenicity and safety of three different dose schedules of a tetravalent dengue vaccine (TAK-003) over a 48-month period in children living in dengue-endemic countries.We did a large, phase 2, double-blind (...) , placebo-controlled trial at three sites in the Dominican Republic, Panama, and the Philippines. Healthy participants aged 2-17 years were randomly assigned 1:2:5:1 using an interactive web response system with stratification by age to receive either a two-dose primary series (days 1 and 91), one primary dose (day 1), one primary dose plus booster (days 1 and 365), or placebo. Participants and relevant study personnel were masked to the random assignment until completion of the study at month 48

2020 Lancet

96. Sit stand desks to reduce sedentary behaviour in 9- to 10-year-olds: the Stand Out in Class pilot cluster RCT Full Text available with Trip Pro

Sit stand desks to reduce sedentary behaviour in 9- to 10-year-olds: the Stand Out in Class pilot cluster RCT Sit-stand desks to reduce sedentary behaviour in 9- to 10-year-olds: the Stand Out in Class pilot cluster RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you

2020 NIHR HTA programme

97. BSPED Interim Guideline for the Management of Children and Young People under the age of 18 years with Diabetic Ketoacidosis

BSPED Interim Guideline for the Management of Children and Young People under the age of 18 years with Diabetic Ketoacidosis BSPED Interim Guideline for the Management of Children and Young People under the age of 18 years with Diabetic Ketoacidosis The previous guideline for the management of DKA has been revised by the BSPED special interest group in diabetic ketoacidosis following a series of meetings. The relatively limited evidence regarding the management of DKA has been reviewed. Where (...) young people aged 16-18 years are managed by adult medical teams because of local arrangements, it is considered appropriate for them to be managed using local adult guidelines that the teams are familiar with rather than using potentially unfamiliar paediatric guidelines. Where individuals aged 16-18 are managed by Paediatric teams the Paediatric guidelines should be followed. 2) The ISPAD definition for DKA with acidosis and a bicarbonate of 3.0 mmol per litre has been adopted. The previous BSPED

2020 British Society for Paediatric Endocrinology and Diabetes

98. Interventions for anxiety in mainstream school-aged children with autism spectrum disorder (ASD) Full Text available with Trip Pro

the review as the impact of the intervention on only the ASD sample would be impossible to isolate. To be included in the review, either all participants in a study had to be of mainstream school age or a majority of participants had to be of mainstream school age. This meant that while most studies involved young people aged 6–16 years, one study (Piravej_2009) included some younger children (minimum 3 years old) and six studies included slightly older participants (MacKinnon_2014, Pryor_2016 (...) of anxiety for those with ASD varies widely (e.g., from 13% to 84%), the majority of studies suggest that a realistic estimate is between 40% and 50% (van Steensel, Bögels, & Perrin, ). The majority of studies undertaken exploring anxiety and ASD have focused on very young children, or older adolescents and adults. Fewer studies have been undertaken with school‐aged children, but those studies that have been conducted suggest a high co‐occurrence of anxiety in ASD populations of this age group (Ashburner

2020 Campbell Collaboration

99. Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD)

in nAMD and occurs in response to abnormally high levels of vascular endothelial growth factor (VEGF). Left untreated, AMD can lead to rapid, irreversible vision loss. nAMD is the leading cause of severe vision loss and legal blindness among individuals aged >65 years in Europe, North America, Australia and Asia (2, 3). Prevalence estimates suggest that nAMD affects approximately 1.7 million people in Europe (4, 5). The estimated incidence of late AMD in Europe in 2013 was between 2.9 and 3.7 per 1000 (...) , 8.1 6.4, 8.8 LSMD (SE) ?0.2 (1.00) ?0.7 (0.86) 95% CI for LSMD ?2.1, 1.8 ?2.4, 1.0 p-value for treatment difference (2-sided) 0.8695 0.4199 p-value for noninferiority (4- letter margin; 1-sided) 65 years in Europe, North America, Australia and Asia, and impacts an estimated 20–25 million people worldwide (2, 3). Prevalence reports have estimated that nAMD affects approximately 1.7 million people in Europe (4, 5). In developed nations, the estimated increase in population ageing is a contributing

2020 EUnetHTA

100. Inferior stabilization of cementless compared with cemented dual-mobility cups in elderly osteoarthrosis patients: a randomized controlled radiostereometry study on 60 patients with 2 years` follow-up Full Text available with Trip Pro

Inferior stabilization of cementless compared with cemented dual-mobility cups in elderly osteoarthrosis patients: a randomized controlled radiostereometry study on 60 patients with 2 years` follow-up Inferior Stabilization of Cementless Compared With Cemented Dual-Mobility Cups in Elderly Osteoarthrosis Patients: A Randomized Controlled Radiostereometry Study on 60 Patients With 2 Years' Follow-Up - PubMed This site needs JavaScript to work properly. Please enable it to take advantage (...) any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Acta Orthop Actions . 2020 Feb 6;1-8. doi: 10.1080/17453674.2020.1720978. Online ahead of print. Inferior Stabilization of Cementless Compared With Cemented Dual-Mobility Cups in Elderly Osteoarthrosis Patients: A Randomized Controlled Radiostereometry Study on 60 Patients With 2 Years' Follow-Up , , , Affiliations Expand

2020 EvidenceUpdates